The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis
This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate wa...
Gespeichert in:
| Veröffentlicht in: | Journal of bone and mineral metabolism 2013-03, Vol.31 (2), p.206-211 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 211 |
|---|---|
| container_issue | 2 |
| container_start_page | 206 |
| container_title | Journal of bone and mineral metabolism |
| container_volume | 31 |
| creator | Itoh, Soichiro Sekino, Yohichi Shinomiya, Ken-ichi Takeda, Shu |
| description | This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone. |
| doi_str_mv | 10.1007/s00774-012-0406-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1323807831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1323807831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-d5ffc8f431b4ca7a4c0cb67d58814913119d4bc39e9a9be3c21d101b1ac6a0833</originalsourceid><addsrcrecordid>eNp1kU1rHSEUhqU0NLc3_QHdFKGbbqb1jDrqsoT0AwLdJGtxnGOv4c44VYfSfx8vNy2l0IWKnMfHoy8hr4G9B8bUh9ImJToGfccEGzrzjOxAcNnJgYnnZMcMiE4rZS7Jy1IeGAMlFbwglz0Hrrnsd2S7OyDFENDXQlOgORacclpcReqmOS6xVMw40bhQn-YxtkpMC_0Z64E6uuZU227d5rURhzjGmjINbdTmrRldnXGpJ3NqorSmnEosV-QiuGPBV0_rntx_urm7_tLdfvv89frjbeeF1LWbZAheB8FhFN4pJzzz46AmqTUIAxzATGL03KBxZkTue5iAwQjOD45pzvfk3dnb-vyxYal2jsXj8egWTFuxwHuumdLtO_bk7T_oQ9ry0rprFMhemoGfhHCmfHtHyRjsmuPs8i8LzJ4ysedMbMvEnjKxpp1582TexhmnPyd-h9CA_gyUVlq-Y_7r6v9aHwHyMJiB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1315259633</pqid></control><display><type>article</type><title>The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Itoh, Soichiro ; Sekino, Yohichi ; Shinomiya, Ken-ichi ; Takeda, Shu</creator><creatorcontrib>Itoh, Soichiro ; Sekino, Yohichi ; Shinomiya, Ken-ichi ; Takeda, Shu</creatorcontrib><description>This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone.</description><identifier>ISSN: 0914-8779</identifier><identifier>EISSN: 1435-5604</identifier><identifier>DOI: 10.1007/s00774-012-0406-9</identifier><identifier>PMID: 23138352</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Alkaline phosphatase ; biomarkers ; Bisphosphonates ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - adverse effects ; Bone Density Conservation Agents - therapeutic use ; Bone mineral density ; Collagen (type I) ; Creatinine ; Data processing ; Drug Therapy, Combination ; Etidronic Acid - administration & dosage ; Etidronic Acid - adverse effects ; Etidronic Acid - analogs & derivatives ; Etidronic Acid - therapeutic use ; Female ; Fitness ; Humans ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Original Article ; Orthopedics ; Osteoporosis ; Osteoporosis - complications ; Osteoporosis - drug therapy ; Osteoporotic Fractures - complications ; Osteoporotic Fractures - drug therapy ; Parathyroid hormone ; Proton Pump Inhibitors - administration & dosage ; Proton Pump Inhibitors - adverse effects ; Proton Pump Inhibitors - therapeutic use ; Protons ; Risedronate Sodium ; Risedronic acid ; Sodium ; Spine (lumbar) ; Statistics</subject><ispartof>Journal of bone and mineral metabolism, 2013-03, Vol.31 (2), p.206-211</ispartof><rights>The Japanese Society for Bone and Mineral Research and Springer Japan 2012</rights><rights>The Japanese Society for Bone and Mineral Research and Springer Japan 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-d5ffc8f431b4ca7a4c0cb67d58814913119d4bc39e9a9be3c21d101b1ac6a0833</citedby><cites>FETCH-LOGICAL-c458t-d5ffc8f431b4ca7a4c0cb67d58814913119d4bc39e9a9be3c21d101b1ac6a0833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00774-012-0406-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00774-012-0406-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23138352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Itoh, Soichiro</creatorcontrib><creatorcontrib>Sekino, Yohichi</creatorcontrib><creatorcontrib>Shinomiya, Ken-ichi</creatorcontrib><creatorcontrib>Takeda, Shu</creatorcontrib><title>The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis</title><title>Journal of bone and mineral metabolism</title><addtitle>J Bone Miner Metab</addtitle><addtitle>J Bone Miner Metab</addtitle><description>This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone.</description><subject>Alkaline phosphatase</subject><subject>biomarkers</subject><subject>Bisphosphonates</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone mineral density</subject><subject>Collagen (type I)</subject><subject>Creatinine</subject><subject>Data processing</subject><subject>Drug Therapy, Combination</subject><subject>Etidronic Acid - administration & dosage</subject><subject>Etidronic Acid - adverse effects</subject><subject>Etidronic Acid - analogs & derivatives</subject><subject>Etidronic Acid - therapeutic use</subject><subject>Female</subject><subject>Fitness</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporosis</subject><subject>Osteoporosis - complications</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporotic Fractures - complications</subject><subject>Osteoporotic Fractures - drug therapy</subject><subject>Parathyroid hormone</subject><subject>Proton Pump Inhibitors - administration & dosage</subject><subject>Proton Pump Inhibitors - adverse effects</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Protons</subject><subject>Risedronate Sodium</subject><subject>Risedronic acid</subject><subject>Sodium</subject><subject>Spine (lumbar)</subject><subject>Statistics</subject><issn>0914-8779</issn><issn>1435-5604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU1rHSEUhqU0NLc3_QHdFKGbbqb1jDrqsoT0AwLdJGtxnGOv4c44VYfSfx8vNy2l0IWKnMfHoy8hr4G9B8bUh9ImJToGfccEGzrzjOxAcNnJgYnnZMcMiE4rZS7Jy1IeGAMlFbwglz0Hrrnsd2S7OyDFENDXQlOgORacclpcReqmOS6xVMw40bhQn-YxtkpMC_0Z64E6uuZU227d5rURhzjGmjINbdTmrRldnXGpJ3NqorSmnEosV-QiuGPBV0_rntx_urm7_tLdfvv89frjbeeF1LWbZAheB8FhFN4pJzzz46AmqTUIAxzATGL03KBxZkTue5iAwQjOD45pzvfk3dnb-vyxYal2jsXj8egWTFuxwHuumdLtO_bk7T_oQ9ry0rprFMhemoGfhHCmfHtHyRjsmuPs8i8LzJ4ysedMbMvEnjKxpp1582TexhmnPyd-h9CA_gyUVlq-Y_7r6v9aHwHyMJiB</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Itoh, Soichiro</creator><creator>Sekino, Yohichi</creator><creator>Shinomiya, Ken-ichi</creator><creator>Takeda, Shu</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20130301</creationdate><title>The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis</title><author>Itoh, Soichiro ; Sekino, Yohichi ; Shinomiya, Ken-ichi ; Takeda, Shu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-d5ffc8f431b4ca7a4c0cb67d58814913119d4bc39e9a9be3c21d101b1ac6a0833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alkaline phosphatase</topic><topic>biomarkers</topic><topic>Bisphosphonates</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone mineral density</topic><topic>Collagen (type I)</topic><topic>Creatinine</topic><topic>Data processing</topic><topic>Drug Therapy, Combination</topic><topic>Etidronic Acid - administration & dosage</topic><topic>Etidronic Acid - adverse effects</topic><topic>Etidronic Acid - analogs & derivatives</topic><topic>Etidronic Acid - therapeutic use</topic><topic>Female</topic><topic>Fitness</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporosis</topic><topic>Osteoporosis - complications</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporotic Fractures - complications</topic><topic>Osteoporotic Fractures - drug therapy</topic><topic>Parathyroid hormone</topic><topic>Proton Pump Inhibitors - administration & dosage</topic><topic>Proton Pump Inhibitors - adverse effects</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Protons</topic><topic>Risedronate Sodium</topic><topic>Risedronic acid</topic><topic>Sodium</topic><topic>Spine (lumbar)</topic><topic>Statistics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Itoh, Soichiro</creatorcontrib><creatorcontrib>Sekino, Yohichi</creatorcontrib><creatorcontrib>Shinomiya, Ken-ichi</creatorcontrib><creatorcontrib>Takeda, Shu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of bone and mineral metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Itoh, Soichiro</au><au>Sekino, Yohichi</au><au>Shinomiya, Ken-ichi</au><au>Takeda, Shu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis</atitle><jtitle>Journal of bone and mineral metabolism</jtitle><stitle>J Bone Miner Metab</stitle><addtitle>J Bone Miner Metab</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>31</volume><issue>2</issue><spage>206</spage><epage>211</epage><pages>206-211</pages><issn>0914-8779</issn><eissn>1435-5604</eissn><abstract>This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>23138352</pmid><doi>10.1007/s00774-012-0406-9</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-8779 |
| ispartof | Journal of bone and mineral metabolism, 2013-03, Vol.31 (2), p.206-211 |
| issn | 0914-8779 1435-5604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1323807831 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Alkaline phosphatase biomarkers Bisphosphonates Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Bone mineral density Collagen (type I) Creatinine Data processing Drug Therapy, Combination Etidronic Acid - administration & dosage Etidronic Acid - adverse effects Etidronic Acid - analogs & derivatives Etidronic Acid - therapeutic use Female Fitness Humans Medicine Medicine & Public Health Metabolic Diseases Middle Aged Original Article Orthopedics Osteoporosis Osteoporosis - complications Osteoporosis - drug therapy Osteoporotic Fractures - complications Osteoporotic Fractures - drug therapy Parathyroid hormone Proton Pump Inhibitors - administration & dosage Proton Pump Inhibitors - adverse effects Proton Pump Inhibitors - therapeutic use Protons Risedronate Sodium Risedronic acid Sodium Spine (lumbar) Statistics |
| title | The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A45%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20risedronate%20administered%20in%20combination%20with%20a%20proton%20pump%20inhibitor%20for%20the%20treatment%20of%20osteoporosis&rft.jtitle=Journal%20of%20bone%20and%20mineral%20metabolism&rft.au=Itoh,%20Soichiro&rft.date=2013-03-01&rft.volume=31&rft.issue=2&rft.spage=206&rft.epage=211&rft.pages=206-211&rft.issn=0914-8779&rft.eissn=1435-5604&rft_id=info:doi/10.1007/s00774-012-0406-9&rft_dat=%3Cproquest_cross%3E1323807831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1315259633&rft_id=info:pmid/23138352&rfr_iscdi=true |